Literature DB >> 24890462

Carbon monoxide-bound red blood cell resuscitation ameliorates hepatic injury induced by massive hemorrhage and red blood cell resuscitation via hepatic cytochrome P450 protection in hemorrhagic shock rats.

Shigeru Ogaki1, Kazuaki Taguchi2, Hiroshi Watanabe3, Yu Ishima1, Masaki Otagiri4, Toru Maruyama5.   

Abstract

Red blood cell (RBC) transfusions are the gold standard in cases of massive hemorrhage, but induce hepatic ischemia-reperfusion injury, a serious complication associated with hemorrhage and RBC resuscitation. Thus, the development of a novel resuscitable fluid that is not associated with hepatic ischemia-reperfusion injury would be desirable. It was reported that exogenous carbon monoxide (CO) treatment ameliorated hepatic ischemia-reperfusion injury accompanying liver transplantation. This suggests that transfusions with CO-bound RBC (CO-RBC) might protect against hepatic ischemia-reperfusion injury following massive hemorrhage and resuscitation compared with RBC resuscitation. To investigate this, we created a hemorrhagic shock model rat, followed by resuscitation with RBC and CO-RBC. Hepatic ischemia-reperfusion injury and the destruction of hepatic cytochrome P450 (CYP) were significantly ameliorated in the CO-RBC resuscitation group compared with the RBC resuscitation group. The free heme derived from the destruction of hepatic CYP was correlated with hepatic oxidation and injury, suggesting that CO-RBC was a major factor in the amelioration of hepatic ischemia-reperfusion injury induced by hemorrhage and resuscitation via hepatic CYP protection. These results indicate that CO-RBC has potential for use as a resuscitative fluid in blood transfusion and does not suffer from the limitations associated with the RBC transfusions that are currently in use.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  cytochrome P450; drug effects; drug transport; hepatic metabolism; pharmacokinetics

Mesh:

Substances:

Year:  2014        PMID: 24890462     DOI: 10.1002/jps.24029

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Long-Term Stored Hemoglobin-Vesicles, a Cellular Type of Hemoglobin-Based Oxygen Carrier, Has Resuscitative Effects Comparable to That for Fresh Red Blood Cells in a Rat Model with Massive Hemorrhage without Post-Transfusion Lung Injury.

Authors:  Masahiro Tokuno; Kazuaki Taguchi; Keishi Yamasaki; Hiromi Sakai; Masaki Otagiri
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

Review 2.  Pre-conditions for eliminating mitochondrial dysfunction and maintaining liver function after hepatic ischaemia reperfusion.

Authors:  Chenxia Hu; Lanjuan Li
Journal:  J Cell Mol Med       Date:  2017-03-16       Impact factor: 5.310

Review 3.  Emerging medical therapies in crush syndrome - progress report from basic sciences and potential future avenues.

Authors:  Ning Li; Xinyue Wang; Pengtao Wang; Haojun Fan; Shike Hou; Yanhua Gong
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

4.  A bioinspired carbon monoxide delivery system prevents acute kidney injury and the progression to chronic kidney disease.

Authors:  Taisei Nagasaki; Hitoshi Maeda; Kazuaki Taguchi; Hiroki Yanagisawa; Kento Nishida; Kazuki Kobayashi; Naoki Wada; Isamu Noguchi; Ryota Murata; Hiromi Sakai; Hiroaki Kitagishi; Junji Saruwatari; Hiroshi Watanabe; Masaki Otagiri; Toru Maruyama
Journal:  Redox Biol       Date:  2022-06-22       Impact factor: 10.787

Review 5.  Potential Use of Biological Proteins for Liver Failure Therapy.

Authors:  Kazuaki Taguchi; Keishi Yamasaki; Hakaru Seo; Masaki Otagiri
Journal:  Pharmaceutics       Date:  2015-08-31       Impact factor: 6.321

6.  The protective effects of carboxyhemoglobin during the resuscitation from hemorrhagic shock in rats.

Authors:  Hongyu Liu; Songyan Yu; Yaojun Peng; Xin Chang; Xinguang Yu
Journal:  Oncotarget       Date:  2017-06-28

7.  Liposomal Artificial Red Blood Cell-Based Carbon Monoxide Donor Is a Potent Renoprotectant against Cisplatin-Induced Acute Kidney Injury.

Authors:  Kazuaki Taguchi; Yuto Suzuki; Moeko Tsutsuura; Kana Hiraoka; Yuki Watabe; Yuki Enoki; Masaki Otagiri; Hiromi Sakai; Kazuaki Matsumoto
Journal:  Pharmaceutics       Date:  2021-12-27       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.